Harrow (HROW) Non Operating Investment Income (2017 - 2024)
Harrow (HROW) posted quarterly Non Operating Investment Income of -$1.9 million for Q2 2024, down 169.33% year-over-year from $2.8 million in Q3 2023, and down 54.09% quarter-over-quarter from -$1.2 million in Q1 2024.
Harrow (HROW) Non Operating Investment Income (2017 - 2024) Analysis & Trends
Harrow's Non Operating Investment Income history runs 8 years deep, the most recent figure standing at -$1.9 million for Q2 2024.
- In Q2 2024, Non Operating Investment Income fell 169.33% year-over-year to -$1.9 million; the TTM figure through Dec 2024 stood at -$3.2 million (down 202.55% YoY), while the FY2024 annual figure was -$3.2 million, down 202.55% from the prior year.
- Non Operating Investment Income for Q2 2024 stood at -$1.9 million, down from -$1.2 million in the prior quarter.
- The five-year high for Non Operating Investment Income was $4.8 million in Q4 2020, with the low at -$10.8 million in Q1 2020.
- The 5-year median for Non Operating Investment Income is -$893500.0 (2020), against an average of -$1.1 million.
- The sharpest annual moves came in 2020 and 2023: Non Operating Investment Income sank 4365.02% in 2020, then jumped 1369.06% in 2023.
- Harrow's Non Operating Investment Income stood at $4.8 million in 2020, then plunged by 131.04% to -$1.5 million in 2021, then soared by 195.97% to $1.4 million in 2022, then slumped by 70.85% to $416000.0 in 2023, then plunged by 562.26% to -$1.9 million in 2024.
- Business Quant data shows HROW's Non Operating Investment Income at -$1.9 million in Q2 2024, -$1.2 million in Q1 2024, and $416000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.81 Bn | 42.84 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.29 Bn | 39.63 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.59 Bn | 29.91 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.67 Bn | 22.88 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.24 Bn | 19.58 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.71 Bn | 15.32 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.09 Bn | 11.56 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Harrow | 1.58 Bn | 1.50 Bn | 50.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -1.92 Mn |
| Jun 30, 2024 | -1.92 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Mar 31, 2024 | -1.25 Mn |
| Dec 31, 2023 | 416,000.00 |
| Dec 31, 2023 | 416,000.00 |
| Sep 30, 2023 | 1.35 Mn |
| Sep 30, 2023 | 1.35 Mn |
| Jun 30, 2023 | -714,000.00 |
| Jun 30, 2023 | -714,000.00 |
| Mar 31, 2023 | 2.04 Mn |
| Mar 31, 2023 | 2.04 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Jun 30, 2022 | -3.45 Mn |
| Mar 31, 2022 | 139,000.00 |
| Mar 31, 2022 | 139,000.00 |